Epilepsy
Conditions
Brief summary
Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy
Detailed description
Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy. Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy . Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)
Interventions
DRUGMemantine Hydrochloride
Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
DRUGPlacebo
Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Intervention model description
100 patients divided into two groups each group 50patients
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Patients with idiopathic epilepsy. * Normal brain imaging (CT brain). * Patients on anti epileptic drugs more than 6 months. * No more than two fits per month. * Score of Mini mental state examination (10-24), mild and moderate cognitive impairment. * No other medical disorders.
Exclusion criteria
* Progressive neurological diseases. * Abnormal brain imaging (CT brain). * More than two fits per month. * Patients with severe cognitive impairment, score of MMSE less than10. * Patients with severe medical disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Memory Assessment Scale (MAS) | 1.5years | This comprehensive battery assesses short-term, verbal and visual memory functioning. |
| Wechsler Adult Intelligence Scale (WAIS) | 1.5years | Intelligence quotient (IQ) tests are the primary clinical instruments used to measure adult and adolescent intellience. |
| Brief Visuospatial Memory Test-Revised (BVMT-R) | 1.5years | The current revised version of the BVMT, a visual display of six simple figures arranged in a 2 × 3 matrix on an 8 × 11 booklet is shown to participants for three consecutive 10-second trials. |
Countries
Egypt
Outcome results
None listed